On Monday, Nov. 5, Akcea Therapeutics AKCA will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
Analysts are expecting Akcea to report a loss of 80 cents per share. Revenue will likely be around $16.82 million, according to the consensus estimate.
In the same quarter last year, Akcea reported an EPS loss of 18 cents on revenue of $13.44 million. Sales would be up 25.07 percent from the year-ago period. Akcea's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | -1.24 | -0.37 | -0.19 | -0.19 |
| EPS Actual | -0.72 | -0.44 | -0.27 | -0.18 |
Stock Performance
Over the last 52-week period, shares are up 46.31 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The average rating by analysts on Akcea stock is a Sell. The strength of this rating has dwindled over the past 90 days.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
